Get started

Financials · BVS

Bioventus Inc. (BVS) financials

For the twelve months ended Sep 26, 2026, Bioventus Inc. reported $585.64M of revenue and $57.30M of net income.

Revenue, TTM
$585.64M
Revenue growth, YoY
+3.9%
Net income, TTM
$57.30M
Net income growth, YoY
+655.0%
Net margin
9.8%
Free cash flow, TTM
$84.98M
EPS, diluted, TTM
$0.80
Cash
$30.71M
Total debt
$229.83M
P/E
16.21
P/S
1.59
Market cap
$928.6M
Annual revenue$568.09M
FY2019FY2025
Annual net income$22.73M
FY2019FY2025
Annual free cash flow$72.11M
FY2019FY2025

BVS revenue and earnings growth

BVS revenueQ3 2026$142.44M

Quarter YoY
+2.7%
QoQ
-7.0%
FY YoY
-0.9%
5Y CAGR
+12.1%

BVS revenue was $142.44M in fiscal Q3 2026 (ended Sep 26, 2026), up 2.7% from a year earlier and down 7.0% from the prior quarter. For the full fiscal 2025 it was $568.09M, down 0.9% from fiscal 2024. Compound annual growth was +12.1% over 5 years. It rose in 4 of the last 6 fiscal years.

BVS net incomeQ3 2026$5.99M

Quarter YoY
+89.8%
QoQ
-82.1%
5Y CAGR
+6.7%

BVS net income was $5.99M in fiscal Q3 2026 (ended Sep 26, 2026), up 89.8% from a year earlier and down 82.1% from the prior quarter. For the full fiscal 2025 it was $22.73M, compared with -$36.13M in fiscal 2024. Compound annual growth was +6.7% over 5 years. Fiscal 2025 is the highest of the 7 fiscal years on file.

BVS EPSQ3 2026$0.08

Quarter YoY
+60.0%
QoQ
-83.0%

BVS diluted EPS was $0.08 in fiscal Q3 2026 (ended Sep 26, 2026), up 60.0% from a year earlier and down 83.0% from the prior quarter. For the full fiscal 2025 it was $0.33, compared with -$0.56 in fiscal 2024.

BVS free cash flowQ3 2026$20.32M

Quarter YoY
-31.4%
QoQ
+7.5%
FY YoY
+90.8%
5Y CAGR
+5.5%

BVS free cash flow was $20.32M in fiscal Q3 2026 (ended Sep 26, 2026), down 31.4% from a year earlier and up 7.5% from the prior quarter. For the full fiscal 2025 it was $72.11M, up 90.8% from fiscal 2024. Compound annual growth was +5.5% over 5 years. Fiscal 2025 is the highest of the 7 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$568.09M$573.28M$512.35M$512.12M$430.90M$321.16M$340.14M
Cost of revenue$179.93M$185.05M$184.15M$181.04M$128.19M$87.64M$90.94M
Gross profit$388.16M$388.23M$328.19M$331.08M$302.71M$233.52M$249.21M
Research and development$12.11M$13.95M$13.45M$23.85M$19.04M$11.20M$11.05M
Selling, general and admin$314.03M$343.80M$303.88M$332.13M$254.25M$193.08M$198.47M
Operating income$53.98M-$15.20M-$81.72M-$167.23M$12.06M$21.24M$31.19M
Pre-tax income$25.71M-$52.34M-$121.11M-$189.03M$9.49M$15.91M$9.69M
Income tax-$1.56M-$5.29M$85.0K-$44.37M-$1.97M$1.19M$1.58M
Net income$22.73M-$36.13M-$156.23M-$158.70M$19.38M$16.41M$6.85M
EPS, basic$0.34-$0.56-$2.49-$2.59-$0.15--
EPS, diluted$0.33-$0.56-$2.49-$2.59-$0.15--
Diluted shares68.9M64.5M62.6M61.4M45.5M--

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$51.24M$41.58M$36.96M$31.84M$99.21M$86.84M$64.52M
Receivables$128.30M$127.39M$122.79M$136.29M$124.96M$88.28M-
Inventory$82.24M$92.47M$91.33M$84.77M$61.69M$29.12M-
Current assets$272.84M$275.61M$268.00M$272.57M$263.10M$211.79M-
Goodwill$7.46M$7.46M$7.46M$7.46M$147.62M$49.80M-
Total assets$683.56M$727.96M$810.91M$1.37B$1.23B$494.47M-
Current liabilities$160.38M$210.40M$175.50M$304.02M$180.86M$122.59M-
Short-term debt$15.00M$27.34M$27.85M$33.06M$18.04M$15.00M-
Long-term debt$278.95M$308.29M$367.00M$385.01M$339.64M$173.38M-
Total debt$293.95M$335.63M$394.85M$418.07M$357.68M$188.38M-
Total liabilities$455.11M$542.35M$589.79M$960.43M$618.21M$350.31M-
Shareholders' equity$184.10M$185.60M$221.12M$412.22M$607.66M--

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow$74.67M$38.80M$15.34M-$13.54M$22.99M$71.80M$40.71M
Capital expenditures$2.56M$1.01M$7.36M$1.48M$13.52M$16.58M$2.34M
Free cash flow$72.11M$37.79M$7.98M-$15.02M$9.47M$55.22M$38.37M
Investing cash flow-$3.25M$22.96M$15.81M-$116.44M-$283.76M-$20.50M-$7.91M
Financing cash flow-$62.14M-$54.58M-$26.65M$62.08M$273.37M-$29.57M-$10.95M
Stock-based compensation$12.67M$13.27M$2.72M$17.59M$19.84M$0$0
Depreciation and amortization$47.01M$49.55M$57.37M$55.40M$34.88M$28.64M$30.32M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY-0.9%11.9%0.0%18.8%34.2%-5.6%-
Net income growth, YoY----18.1%139.5%-
Gross margin68.3%67.7%64.1%64.6%70.3%72.7%73.3%
Operating margin9.5%-2.7%-16.0%-32.7%2.8%6.6%9.2%
Net margin4.0%-6.3%-30.5%-31.0%4.5%5.1%2.0%
Free cash flow margin12.7%6.6%1.6%-2.9%2.2%17.2%11.3%
Return on equity12.3%-19.5%-70.7%-38.5%3.2%--
Return on assets3.3%-5.0%-19.3%-11.6%1.6%3.3%-
Current ratio1.701.311.530.901.451.73-
Debt to equity1.601.811.791.010.59--

Source: XBRL data Bioventus Inc. files with the SEC, latest filing dated Nov 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BVS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
BVS$585.64M+3.9%$57.30M9.8%$928.6M
SYK$26.30B+7.9%$3.62B13.8%$124.00B
MMM$25.25B+1.7%$3.54B14.0%$97.47B
BSX$21.07B+8.9%$3.50B16.6%$63.81B
BDX$23.25B+17.4%$941.00M4.0%$58.63B
MDLN$30.68B-$683.00M2.2%$53.55B
RMD$5.73B+9.0%$1.59B27.8%$33.16B
DXCM$5.10B+13.0%$991.00M19.4%$30.24B
WST$3.40B+12.6%$638.90M18.8%$28.78B

BVS FAQ

9 questions
  • What is BVS revenue?
    Bioventus Inc. (BVS) reported $585.64M of revenue for the twelve months ended Sep 26, 2026. That is up 3.9% from the year before. Revenue for fiscal 2025 was $568.09M.
  • Is BVS profitable?
    Yes. Bioventus Inc. earned $57.30M in net income for the twelve months ended Sep 26, 2026, a net margin of 9.8%.
  • How much cash and debt does BVS have?
    Bioventus Inc. reported $30.71M in cash and cash equivalents and $229.83M of debt on its most recent balance sheet in SEC filings.
  • How fast is BVS revenue growing?
    Bioventus Inc.'s revenue changed -0.9% in fiscal 2025, to $568.09M. Its compound annual growth rate was +12.1% over 5 years.
  • What is BVS gross margin?
    Bioventus Inc.'s gross profit was $402.35M on $585.64M of revenue for the twelve months ended Sep 26, 2026, a gross margin of 68.7%.
  • What is BVS free cash flow?
    Bioventus Inc. generated $84.98M of free cash flow for the twelve months ended Sep 26, 2026, which is operating cash flow of $87.43M less capital expenditures.
  • What is BVS earnings per share?
    Diluted earnings per share were $0.80 for the twelve months ended Sep 26, 2026, from SEC filings, restated for any stock split those filings show.
  • When did BVS last report financial results?
    The latest statements here come from Bioventus Inc.'s 10-Q filed on Nov 2, 2026, covering the period ended Sep 26, 2026.
  • Where does this BVS financial data come from?
    Quantisnow builds these statements from the structured XBRL data Bioventus Inc. files with the SEC. It is provided for information only and is not investment advice.